422 related articles for article (PubMed ID: 18229422)
1. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
[TBL] [Abstract][Full Text] [Related]
3. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
5. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Tran TT; Uhl M; Ma JY; Janssen L; Sriram V; Aulwurm S; Kerr I; Lam A; Webb HK; Kapoun AM; Kizer DE; McEnroe G; Hart B; Axon J; Murphy A; Chakravarty S; Dugar S; Protter AA; Higgins LS; Wick W; Weller M; Wong DH
Neuro Oncol; 2007 Jul; 9(3):259-70. PubMed ID: 17522330
[TBL] [Abstract][Full Text] [Related]
7. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
8. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma.
Venkatasubbarao K; Ahmed MM; Mohiuddin M; Swiderski C; Lee E; Gower WR; Salhab KF; McGrath P; Strodel W; Freeman JW
Anticancer Res; 2000; 20(1A):43-51. PubMed ID: 10769633
[TBL] [Abstract][Full Text] [Related]
10. Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer.
Matsuzaki K; Kitano C; Murata M; Sekimoto G; Yoshida K; Uemura Y; Seki T; Taketani S; Fujisawa J; Okazaki K
Cancer Res; 2009 Jul; 69(13):5321-30. PubMed ID: 19531654
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor beta signaling via Ras in mesenchymal cells requires p21-activated kinase 2 for extracellular signal-regulated kinase-dependent transcriptional responses.
Suzuki K; Wilkes MC; Garamszegi N; Edens M; Leof EB
Cancer Res; 2007 Apr; 67(8):3673-82. PubMed ID: 17440079
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
13. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway.
Yoo YA; Kang MH; Kim JS; Oh SC
Carcinogenesis; 2008 Mar; 29(3):480-90. PubMed ID: 18174246
[TBL] [Abstract][Full Text] [Related]
14. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
Park CY; Kim DK; Sheen YY
Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
[TBL] [Abstract][Full Text] [Related]
15. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
Tian F; Byfield SD; Parks WT; Stuelten CH; Nemani D; Zhang YE; Roberts AB
Cancer Res; 2004 Jul; 64(13):4523-30. PubMed ID: 15231662
[TBL] [Abstract][Full Text] [Related]
16. Differential TGF-{beta} signaling in retinal vascular cells: a role in diabetic retinopathy?
Van Geest RJ; Klaassen I; Vogels IM; Van Noorden CJ; Schlingemann RO
Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):1857-65. PubMed ID: 19959647
[TBL] [Abstract][Full Text] [Related]
17. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
18. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
Van Aarsen LA; Leone DR; Ho S; Dolinski BM; McCoon PE; LePage DJ; Kelly R; Heaney G; Rayhorn P; Reid C; Simon KJ; Horan GS; Tao N; Gardner HA; Skelly MM; Gown AM; Thomas GJ; Weinreb PH; Fawell SE; Violette SM
Cancer Res; 2008 Jan; 68(2):561-70. PubMed ID: 18199553
[TBL] [Abstract][Full Text] [Related]
19. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
Ehata S; Hanyu A; Fujime M; Katsuno Y; Fukunaga E; Goto K; Ishikawa Y; Nomura K; Yokoo H; Shimizu T; Ogata E; Miyazono K; Shimizu K; Imamura T
Cancer Sci; 2007 Jan; 98(1):127-33. PubMed ID: 17129361
[TBL] [Abstract][Full Text] [Related]
20. c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma.
Kiyono K; Suzuki HI; Morishita Y; Komuro A; Iwata C; Yashiro M; Hirakawa K; Kano MR; Miyazono K
Cancer Sci; 2009 Oct; 100(10):1809-16. PubMed ID: 19594546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
